- $36.7 million in first full quarter of U.S. Attruby™ net product revenue and as of April 25, 2025, 2,072 unique patient prescriptions written by 756 unique prescribers - Observational run-in study ...
On 12 February 2026, BridgeBio Pharma reported positive topline Phase 3 PROPEL 3 results for oral infigratinib in children with achondroplasia, showing statistically significant gains in annualized ...
Investor's Business Daily on MSN
BridgeBio unveils positive results for its most 'hotly debated' phase 3 drug
BridgeBio unveiled promising results Thursday for its "hotly debated" final-phase asset: a potential treatment for ...
BridgeBio's pipeline assets like encaleret and BBP-418 offer optionality but lack near-term cash flow and face regulatory ...
BridgeBio Pharma’s stock jumped more than 6% on Thursday after the drugmaker announced promising sales results for its FDA-approved heart drug as part of its latest quarterly earnings release. The ...
BridgeBio Pharma Inc. will report fourth-quarter and full-year 2025 results after the market closes on Tuesday, February 24, a closely watched print for a rare-disease developer seeking to prove its ...
- Preliminary unaudited Q4 and Full Year 2025 net Attruby ® product revenue of $146.0 million and $362.4 million, respectively - Attruby (acoramidis) is rapidly becoming the first-choice therapy for ...
No-moat BridgeBio Pharma reported strong first-quarter results, driven by better-than-expected commercial success of its key asset Attruby, which generated $36.7 million in sales in the period. The ...
No-moat BridgeBio reported fourth-quarter results that were largely in line with our expectations. Investors have reacted positively to BridgeBio’s recent developments and have sent the stock up 30% ...
The stock price of BridgeBio plunged 15% Thursday as Pfizer’s reported decision to withdraw a tafamidis patent in the European Union triggered fears of earlier generic entry in the blockbuster ...
- Observational run-in study for hypochondroplasia Phase 2 trial fully enrolled significantly ahead of schedule. The first participant was also dosed in the Phase 2 interventional study - ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results